Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma

European Journal of Endocrinology

Volumn 170, Issue 4, 2014, Pages 619-625

  Danilovic, Debora L S ^a,b   Lima, Erika U ^a   Domingues, Regina B ^a   Brandão, Lenine G ^a   Hoff, Ana O ^b   Marui, Suemi ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Serviço de Endocrinologia Instituto do Câncer do Estado de São Paulo ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; AGE; ARTICLE; BRAF GENE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIFFERENTIATED THYROID CANCER; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; NECK DISSECTION; ONCOGENE RAS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SURGICAL APPROACH; THYROID CARCINOMA; THYROID NODULE; THYROIDECTOMY; TUMOR INVASION;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; CARCINOMA; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NECK DISSECTION; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84899493011     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0944     Document Type: Article

References (29)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214. (doi:10.1089/thy.2009. 0110)
2. Guth S, Theune U, Aberle J, Galach A & Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. European Journal of Clinical Investigation 2009 39 699-706. (doi:10.1111/j.1365-2362.2009.02162.x)
3. Hegedus L. Clinical practice. The thyroid nodule. New England Journal of Medicine 2004 351 1764-1771. (doi:10.1056/NEJMcp031436)
4. Baloch ZW, Li Volsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, De May RM, Sidawy MK & Frable WJ. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagnostic Cytopathology 2008 36 425-437. (doi:10.1002/dc.20830)
5. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 2003 63 1454-1457.
6. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003 22 4578-4580. (doi:10.1038/sj.onc.1206706)
7. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G et al. BRAF (V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2004 89 2414-2420. (doi:10.1210/jc.2003- 031425)
8. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW & Sidransky D. BRAF T1796A transversion mutation in various thyroid neoplasms. Journal of Clinical Endocrinology and Metabolism 2004 89 1365-1368. (doi:10.1210/jc.2003-031488)
9. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park Do J, Lee HS, Cho BY, Lee ES et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clinical Endocrinology 2006 65 660-666. (doi:10.1111/j.1365-2265. 2006.02646.x)
10. Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E & Degli Uberti EC. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. European Journal of Endocrinology 2009 161 467-473. (doi:10.1530/EJE-09-0353)
11. Xing M, Haugen BR & Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013 381 1058-1069. (doi:10.1016/S0140-6736 (13) 60109-9)
12. Li C, Lee KC, Schneider EB & Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2012 97 4559-4570. (doi:10.1210/jc.2012-2104)
13. Dutenhefner SE, Marui S, Santos AB, Lima EU, Inoue M, Neto JD, Shiang C, Fukushima J, Cernea CR & Friguglietti C. Braf, a tool in the decision to perform elective neck dissection? Thyroid 2013 23 1541-1546. (doi:10.1089/thy.2012.0304)
14. Greene FL. In AJCC Cancer Staging Manual, 6th edn, pp 77-87. New York: Springer-Verlag, 2002.
15. Vince A, Poljak M & Seme K. DNA extraction from archival Giemsastained bone-marrow slides: comparison of six rapid methods. British Journal of Haematology 1998 101 349-351. (doi:10.1046/j.1365-2141. 1998.00702.x)
16. Benlloch S, Paya A, Alenda C, Bessa X, Andreu M, Jover R, Castells A, Llor X, Aranda FI & Massuti B. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. Journal of Molecular Diagnostics 2006 8 540-543. (doi:10.2353/jmoldx.2006.060070)
17. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K & Nikiforova MN. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. Journal of Clinical Endocrinology and Metabolism 2009 94 2092-2098. (doi:10.1210/jc.2009-0247)
18. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, Di Santo A, Caruso G, Carli AF, Brilli L et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. Journal of Clinical Endocrinology and Metabolism 2010 95 1365-1369. (doi:10.1210/jc.2009-2103)
19. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, Li Volsi VA, Mandel SJ et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. New England Journal of Medicine 2012 367 705-715. (doi:10.1056/NEJMoa1203208)
20. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC & Cheng JT. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clinical Endocrinology 2005 63 461-466. (doi:10.1111/j.1365-2265. 2005.02367.x)
21. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-Related Cancer 2006 13 455-464. (doi:10.1677/erc.1.01086)
22. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocrine Journal 2009 56 89-97. (doi:10.1507/endocrj. K08E-208)
23. Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS & Bae JS. Is the BRAF (V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? American Journal of Surgery 2012 203 436-441. (doi:10.1016/j.amjsurg.2011.02.013)
24. Trovisco V, Couto JP, Cameselle-Teijeiro J, De Castro IV, Fonseca E, Soares P & Sobrinho-Simoes M. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clinical Endocrinology 2008 69 683-685. (doi:10.1111/j.1365-2265. 2008.03243.x)
25. Lee KC, Li C, Schneider EB, Wang Y, Somervell H, Krafft M, Umbricht CB & Zeiger MA. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery 2012 152 977-983. (doi:10.1016/j.surg.2012.08.019)
26. Sancisi V, Nicoli D, Ragazzi M, Piana S & Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 2012 97 E1745-E1749. (doi:10.1210/jc.2012-1526)
27. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A & Vitale M. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Journal of Clinical Endocrinology and Metabolism 2012 97 2333-2340. (doi:10.1210/jc.2011-3106)
28. Joo JY, Park JY, Yoon YH, Choi B, Kim JM, Jo YS, Shong M & Koo BS. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. Journal of Clinical Endocrinology and Metabolism 2012 97 3996-4003. (doi:10.1210/jc.2012-2444)
29. Randolph GW, Duh QY, Heller KS, Li Volsi VA, Mandel SJ, Steward DL, Tufano RP & Tuttle RM. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012 22 1144-1152. (doi:10.1089/thy. 2012.0043)